[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasolacrimal-duct-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasolacrimal-duct-obstruction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100658338","outcomes-of-stentless-dacryocystorhinostomy-in-primary-acquired-nasolacrimal-duct-obstruction-100658338",false,"NCT07848932","Outcomes of Stentless Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction.","Outcomes of Stentless Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction","Inclusion Criteria:\n\nAge 16 years or older\n\nSymptoms compatible with lacrimal drainage obstruction, particularly persistent epiphora, for at least 3 months\n\nObjective evidence of primary acquired nasolacrimal duct obstruction (PANDO) by lacrimal irrigation\u002Fprobing and\u002For an accepted lacrimal functional test\n\nIndication for primary dacryocystorhinostomy (DCR) after clinical assessment\n\nAbility to provide informed consent\n\nAbility and willingness to attend the scheduled postoperative visits\n\nExclusion Criteria:\n\nPrevious ipsilateral DCR or other lacrimal drainage surgery\n\nCanalicular or punctal stenosis that independently prevents adequate lacrimal drainage\n\nCongenital nasolacrimal duct obstruction\n\nTraumatic, iatrogenic, neoplastic, granulomatous, or other secondary nasolacrimal duct obstruction\n\nActive uncontrolled acute dacryocystitis at the time of surgery\n\nKnown lacrimal sac or nasal malignancy\n\nPrevious major sinonasal surgery likely to substantially alter the lacrimal anatomy\n\nSevere uncontrolled sinonasal inflammatory disease requiring treatment before DCR\n\nSevere bleeding disorder or contraindication to surgery\n\nInability to comply with postoperative assessment","ALL","16 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This prospective, single-arm interventional clinical study aims to evaluate the short- and intermediate-term anatomical, functional, and quality-of-life outcomes of primary stentless endoscopic dacryocystorhinostomy (En-DCR) in adult patients with primary acquired nasolacrimal duct obstruction (PANDO). Endoscopic DCR bypasses the obstructed distal lacrimal drainage pathway by creating a permanent communication between the lacrimal sac and the nasal cavity. While silicone intubation is traditionally used to prevent early restenosis, its routine use remains controversial due to potential foreign-body morbidity, including canalicular trauma, granuloma formation, tube displacement, and the necessity for a secondary removal procedure. The rationale for this study is based on the concept that surgical success is determined by adequate osteotomy, wide sac marsupialization, mucosal flap preservation, and structured postoperative care, rather than the presence of a permanent foreign body. The study will recruit approximately 40 eligible adults (aged $\\\\ge$16 years) with objectively confirmed, symptomatic PANDO to undergo a standardized stentless En-DCR procedure. Participants will undergo rigorous postoperative clinical and endoscopic assessments at 1 week, 1 month, 3 months, 6 months, and 12 months. The primary endpoint is the overall composite success rate at 12 months, defined by both objective anatomical patency of the rhinostomy (verified via endoscopy and lacrimal irrigation) and clinically meaningful functional resolution of epiphora (Munk score 0-1). Secondary objectives include quantifying changes in disease-specific quality of life using the Lac-Q questionnaire, documenting postoperative endoscopic healing parameters, and evaluating the incidence and mechanisms of surgical failure or complications.",[26,27],"Nasolacrimal Duct Obstruction","Epiphora","NOT_YET_RECRUITING","2026-09-26",{"date":31,"type":32},"2026-09-30","ACTUAL",{"date":34,"type":20},"2027-01-01",{"date":36,"type":20},"2028-06-01",{"name":38,"class":39},"Assiut University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100516062","phase-3-artificial-tears-to-prevent-nasolacrimal-duct-obstruction-in-patients-treated-with-radioactive-iodine-for-thyroid-cancer-100516062","NCT05999630","Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer","The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer","Inclusion Criteria:\n\n1. Radio-iodine therapy for thyroid cancer\n2. Radioiodine therapy ≥150 mCi\n3. Age 18 or older\n\nExclusion Criteria:\n\n1. Use of eye drops, other than artificial tears\n2. History of periocular trauma with tear duct involvement\u002Flacrimal gland trauma\n3. History of lacrimal drainage disease: canaliculitis, dacryocystitis\n4. Prior radiotherapy\n5. Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)\n6. Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)\n7. Nasolacrimal duct obstruction at baseline",true,"18 Years",{"count":50,"type":20},100,[52],"PHASE3","The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.",[26,55],"Thyroid Cancer",[26,57,55],"Artificial Tears","RECRUITING","2025-10-26",{"date":61,"type":32},"2025-10-28",{"date":63,"type":32},"2023-08-21",{"date":65,"type":20},"2027-12-31",{"name":67,"class":39},"Vanderbilt University Medical Center",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100587156","effect-of-standardized-lacrimal-sac-massage-compared-with-probing-for-congenital-lacrimal-duct-obstruction-100587156","NCT06924723","Effect of Standardized Lacrimal Sac Massage Compared With Probing for Congenital Lacrimal Duct Obstruction","Effect of Standardized Lacrimal Sac Massage Compared With Probing for Congenital Lacrimal Duct Obstruction: a Non-inferiority, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age from 3 months to 1 year;\n2. Presence of at least one symptom of CNLDO (tear spillage, mucous discharge) in one or both eyes;\n3. No surgical treatment for NLD (probing, balloon dilation, tube placement, DCR, etc.);\n4. Can cooperate with the examination and subsequent follow-up;\n5. Guardians agreed to be enrolled in the study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Combination of presenting infections of the conjunctiva and cornea;\n2. Combination of other serious ocular surface and intraocular disorders that may affect the therapeutic effect;\n3. Congenital malformation syndromes, developmental delays, facial anomalies, facial deformities; history of surgery or injury to the lacrimal duct, history of punctal occlusion, history of lacrimal fistula, history of congenital bulging of the lacrimal sac, history of acute dacryocystitis, history of severe blepharitis, and perinatal abnormalities such as preterm labor, low birth weight, and so on;","3 Months","1 Year",{"count":79,"type":20},160,[23],"Congenital nasolacrimal duct obstruction (CNLDO) is a common ophthalmic condition in children, presenting with tearing and pus overflow, with a prevalence of 5%-20% within 1 year of age. Although most cases resolve spontaneously within 1 year of age, some children require treatment. Lacrimal sac massage is a non-invasive, easy and cost-effective conservative treatment that helps to unblock the obstruction by increasing the pressure in the tear duct. Studies have shown that massage has a 93% cure rate in children under 8 months of age. In contrast, tear duct probing is effective but invasive and risky. In recent years, with the development of minimally invasive techniques, lacrimal sac massage has received renewed attention, and studies have shown its efficacy to be comparable to probing. However, there are problems of non-standardized massage timing and techniques in clinical practice, which affects the therapeutic efficacy. This study aims to assess whether the efficacy of standardized dacryocystic massage is not inferior to that of dacryocystorhinostomy through a randomized controlled trial, providing a reference for the treatment of CNLDO.",[26],"2025-04-05",{"date":85,"type":32},"2025-04-11",{"date":87,"type":20},"2025-05-01",{"date":89,"type":20},"2026-01-01",{"name":91,"class":39},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]